TCTR20190708002已完成3 期
Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks : a prospect
none0 个研究点目标入组 84 人开始时间: 2019年7月8日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 0 N/A (No limit)（—）
- 性别
- All
入选标准
- •- Age >18 years
- •- HIV-infected Patients
- •- Receiving TDF-based regimen
- •- Virologic control (VL < 40 copies for at least 6 months)
- •- TDF induced proximal renal tubular dysfunction (PRTD) or decline in eGFR of >10% from baseline after TDF treatment
- •- HLA B*5701=negative
排除标准
- •- Pregnancy
- •- HBV infection(Positive for HBS Ag)
- •- TB or active opportunistic infection
- •- Cirrhosis Child-Pugh score B-C
- •- Preexisting kidney disease(chronic kidney disease, ureteric stone, urinary tract obstruction)
研究者
相似试验
已完成
不适用
Efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy in virologically suppressed HIV-infected patientsHIV infectionJPRN-UMIN000038177Kyushu University Hospital Department of General internal medicine120
招募中
3 期
Outcome of early switching of Tenofovir Disoproxil Fumarate (TDF) in HIV-infected patients with TDF-induced nephrotoxicity: a prospective studyTDF-induced proximal renal tubulopathyComplete recoveryHIVTCTR20190307003/A64
招募中
不适用
Efficacy of entecavir-to-tenofovir switching treatment to attain a drug-free state in chronic hepatitis B: a randomized controlled trialchronic hepatitis BJPRN-UMIN000021793Department of Hepatology, Osaka Metropolitan University90
招募中
3 期
Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours vs 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir induced renal dysfunction.chronic hepatitis Brenal impairmentHBV viral controltenofovirdose reductionrenal impairmentTCTR20180207001Gastroenterological Association of Thailand108
进行中（未招募）
1 期
The effect of two related HIV-medicines (TDF and TAF) on small intestine gut wall - could that explain why TDF seems to decrease and TAF to increase body weightHIV-positive people who have good and stable treatment response for HIV-medication which includes either tenofovir disoproxil (TDF) or tenoforvir alafenamide (TAF)EUCTR2022-000849-32-FIHelsinki University Hospital24